

Neuro aktuell

Ausgabe 2-2020

Literatur

Schwerpunkt: Multiple Sklerose

Titel: Die Betreuung schwangerer Multiple-Sklerose-Patientinnen in der Praxis (S. 15–26)

Autoren: H.-K. Goischke

Literatur:

1. Robertson NP et al. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. *Brain* 1996; 119: 449–455
2. Robertson NP et al. Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. *Lancet* 1997; 349: 1587–1590
3. Ebers GC et al. Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group. *Ann Neurol* 2000; 48: 927–931
4. Rasmussen PV et al. Patient awareness about family planning represents a major knowledge gap in multiple sclerosis. *Mult Scler Rel Disord* 2018; 24: 129–134
5. Tuohy O et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. *J Neurol Neurosurg Psychiatry* 2015; 86: 208–215
6. Landi D et al. Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2018; 89: 1272–1278
7. Bove R et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. *Obstet Gynecol* 2014; 124: 1157–1168
8. Dahl J et al. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. *Neurology* 2005; 65: 1961–1963
9. Hellwig K et al. Reproductive counseling, treatment and course of pregnancy in 73 German MS Patients. *Acta Neurol Scand* 2008; 118: 24–28
10. Goischke HK. Alemtuzumab Treatment-Induced Thyroid Dysfunction in Relapsing Remitting MS (RRMS): a Varied Clinical Picture in an Interdisciplinary Terrain. *Akt Neurol* 2018; 45: 44–51
11. Instanes JT et al. Attention-Deficit/Hyperactivity Disorder in Offspring of Mothers with Inflammatory and Immune System Disease. *Biol Psychiatry* 2017; 81: 452–459
12. Ghassabian A et al. Maternal thyroid autoimmunity during pregnancy and the risk of attention deficit/hyperactivity problems in children: the Generation R Study. *Thyroid* 2012; 22: 178–186
13. Zivadinov R et al. Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis. *AJNR Am J Neuroradiol* 2016; 37: 1010–1016
14. Chan S & Boelaert K. Optimal management of hypothyroidism, hypothyroxinaemia and euthyroid TPO antibody positivity preconception and in pregnancy. *Clin Endocrinol (Oxf)* 2015; 82: 313–326
15. Piccinni MP et al. How pregnancy can affect autoimmune diseases progression? *Clin Mol Allergy* 2016; 14: 11

16. Carp HJ et al. The autoimmune bases of infertility and pregnancy loss. *J Autoimmun* 2012; 38: J266–J274
17. Gleicher N et al. Cutting edge assessment of the impact of autoimmunity on female reproductive success. *J Autoimmun* 2012; 38: J74–J80
18. Thöne J et al. Treatment of multiple sclerosis during pregnancy - safety considerations. *Expert Opin Drug Saf* 2017; 16: 523–534
19. Di Gregorio M et al. Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes. *J Neurol* 2018; 265: 522–529
20. Winkelmann A et al. Intravenous immunoglobulin treatment in multiple sclerosis: A prospective, rater-blinded analysis of relapse rates during pregnancy and the postnatal period. *CNS Neurosci Ther* 2019; 25: 78–85
21. Mumford SL et al. Association of preconception serum 25-hydroxyvitamin D concentrations with livebirth and pregnancy loss: a prospective cohort study. *Lancet Diabetes Endocrinol* 2018; 6: 725–732
22. Derakhshandi H et al. Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial. *Acta Neurol Belg* 2013; 113: 257–263
23. Wagner CL et al. Vitamin D administration during pregnancy as prevention for pregnancy, neonatal and postnatal complications. *Rev Endocr Metab Disord* 2017; 18: 307–322
24. Hollis BW & Wagner CL. Vitamin D supplementation during pregnancy: Improvements in birth outcomes and complications through direct genomic alteration. *Mol Cell Endocrinol* 2017; 453: 113–130
25. Stubbs G et al. Will vitamin D supplementation during pregnancy and early childhood reduce the recurrence rate of autism in newborn siblings? *Med Hypotheses* 2016; 88: 74–78
26. Wagner CL et al. Post-hoc analysis of vitamin D status and reduced risk of preterm birth in two vitamin D pregnancy cohorts compared with South Carolina March of Dimes 2009-2011 rates. *J Steroid Biochem Mol Biol* 2016; 155: 245–251
27. De-Regil LM et al. Vitamin D supplementation for women during pregnancy. *Sao Paulo Med J* 2016; 134: 274–275
28. Bi WG et al. Association Between Vitamin D Supplementation During Pregnancy and Offspring Growth, Morbidity, and Mortality: A Systematic Review and Meta-analysis. *JAMA Pediatr* 2018; 172: 635–645
29. Ross AC et al. eds.; Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. *Dietary Reference Intakes for Calcium and Vitamin D*. Washington (DC): National Academies Press; 2011
30. Scientific Advisory Committee on Nutrition (SACN). *Vitamin D and Health*. London: SACN; 2016
31. Laursen JH et al. Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. *Mult Scler Relat Disord* 2016; 10: 169–173
32. Mirzaei F et al. Gestational vitamin D and risk of multiple sclerosis in offspring. *Ann Neurol* 2011; 7: 30–40
33. Munger KL et al. Vitamin D Status During Pregnancy and Risk of Multiple Sclerosis in Offspring of Women in the Finnish Maternity Cohort. *JAMA Neurol* 2016; 73: 515–519

34. Nielsen NM et al. Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study. *Neurology* 2017; 88: 44–51
35. Curtis EM et al. Maternal vitamin D supplementation during pregnancy. *Br Med Bull* 2018; 126: 57–77
36. Bhargava P et al. Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to health controls. *Mult Scler* 2016; 22: 753–760
37. Engler JB et al. Glucocorticoid receptor in T cells mediates protection from autoimmunity in pregnancy. *Proc Natl Acad Sci USA* 2017; 114: E181–E190
38. Jeffery LE et al. 1,25-Dihydroxyvitamin D₃ and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FOXP3. *J Immunol* 2009; 183: 5458–5467
39. Gotta M et al. Use of complementary and alternative medicine in patients with multiple sclerosis in Germany. *Complement Ther Med* 2018; 36: 113–117
40. Skovgaard L. Use and users of complementary and alternative medicine among people with multiple sclerosis in Denmark. *Dan Med J* 2016; 63: B5159
41. Ray JG et al. Association between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. *JAMA* 2016; 316: 952–961
42. Park-Wyllie L et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. *Teratology* 2000; 62: 385–392
43. Singh RR et al. Short- and long-term effects of exposure to natural and synthetic glucocorticoids during development. *Clin Exp Pharmacol Physiol* 2012; 39: 979–989
44. Stark MJ et al. Sex-specific alterations in placental 11beta-hydroxysteroid dehydrogenase 2 activity and early postnatal clinical course following antenatal betamethasone. *Am J Physiol Regul Integr Comp Physiol* 2009; 297: R510–R514
45. Homar V et al. High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn. *Neonatology* 2008; 94: 306–309
46. Kurtoğlu S et al. Fetal adrenal suppression due to maternal corticosteroid use: case report. *J Clin Res Pediatr Endocrinol* 2011; 3: 160–162
47. Saulnier PJ et al. Hypoglycaemic seizure and neonatal acute adrenal insufficiency after maternal exposure to prednisone during pregnancy: a case report. *Eur J Pediatr* 2010; 169: 763–765
48. Fernandez EF & Watterberg KL. Relative adrenal insufficiency in the preterm and term infant. *J Perinatol* 2009; 29: 44–S49
49. Davis EP et al. Prenatal maternal cortisol concentrations predict neurodevelopment in middle childhood. *Psychoneuroendocrinology* 2017; 75: 56–63
50. Chang YP. Evidence for adverse effect of perinatal glucocorticoid use on the developing brain. *Korean J Pediatr* 2014; 57: 101–109
51. Matthews SG et al. Fetal glucocorticoid exposure and hypothalamo-pituitary-adrenal (HPA) function after birth. *Endocr Res* 2004; 30: 827–836
52. Kapoor A et al. Fetal programming of hypothalamic-pituitary-adrenal (HPA) axis function and behavior by synthetic glucocorticoids. *Brain Res Rev* 2008; 57: 586–595
53. Schimrigk S et al. Escalation Therapy of Steroid Refractory Multiple Sclerosis Relapse with Tryptophan Immunadsorption – Observational Multicenter Study with 147 patients. *Eur Neurol* 2016; 75: 300–306

54. Hoffmann F et al. Tryptophan immunadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica. *Ther Adv Neurol Disord* 2018; 11: 1756286418774973
55. Hewitt PE et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. *Lancet* 2014; 384: 1766–1773
56. Marson P et al. Therapeutic apheresis in pregnancy: General considerations and current practice. *Transfus Apher Sci* 2015; 53: 256–261
57. Cox JL et al. Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient. *J Clin Apher* 2017; 32: 191–195
58. Kelly VM et al. Obstetric outcomes in women with multiple sclerosis and epilepsy. *Neurology* 2009; 73: 1831–1836
59. Vukusic S et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. *Brain* 2004; 127: 1353–1360
60. Pastò L et al. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. *BMC Neurol* 2012; 12: 165
61. Harazim H et al. Obstetric anesthesia/analgesia does not affect disease course in multiple sclerosis: 10-years retrospective cohort study. *Brain Behav* 2018; 8: e01082
62. Drust A et al. Anästhesie und Multiple Sklerose – Was gilt es zu beachten? *Anesthesiol Intensivmed Notfallmed Schmerzther* 2016; 51: 458–467
63. Merewood A et al. Association between Vitamin D deficiency and primary cesarean section. *J Clin Endocrinol Metab* 2009; 94: 940–945
64. Hubeish M et al. Maternal Vitamin D Level and Rate of Primary Cesarean Section. *J Clin Gynecol Obstet* 2018; 7: 43–51
65. Miller DH et al. Pregnancy, sex and hormonal factors in multiple sclerosis. *Mult Scler* 2014; 20: 527–536
66. Hellwig K et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. *Ther Adv Neurol Disord* 2012; 5: 247–253
67. Confavreux C et al. Rate of pregnancy-related relapse in multiple sclerosis. *Pregnancy in multiple sclerosis group*. *New Engl J Med* 1998; 339: 285–291
68. Pozilli C & Pugliatti M; ParadigMS Group. An overview of pregnancy-related issues in patients with multiple sclerosis. *Eur J Neurol* 2015; 22: 34–39
69. Alroughani R et al. Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. *Neurology* 2018; 90: e840–e846
70. Brandt-Wouters E et al. The effect of postpartum intravenous immunoglobulins on the relapse rate among patients with multiple sclerosis. *Int J Gynaecol Obstet* 2016; 134: 194–196
71. Shoemaker TJ & Mowry EM. A review of vitamin D supplementation as disease-modifying therapy. *Mult Scler* 2018; 24: 6–11
72. Eidelman AI & Schanler RJ; American Academy of Pediatrics. Breastfeeding and the Use of Human Milk. *Pediatrics* 2012; 129: e827–e841
73. Almas S et al. Management of Multiple Sclerosis in the Breastfeeding Mother. *Mult Scler Int* 2016; 2016: 652748
74. Boz C et al. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis. *Mult Scler* 2018; 24: 1205–1211
75. Cooper SD et al. Transfer of methylprednisolone into breast milk in a mother with multiple sclerosis. *J Hum Lact* 2015; 31: 237–239

76. Barro C et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. *Brain* 2018; 141: 2382–2391
77. Giovannoni G. Peripheral blood neurofilament light chain levels: the neurologist's C-reactive protein? *Brain* 2018; 141: 2235–2237
78. Dobson R et al. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. *Pract Neurol* 2019; 19: 106–114
79. Sharif K et al. Vitamin D, autoimmunity and recurrent pregnancy loss: More than an association. *Am J Reprod Immunol* 2018; 80: e12991
80. Bagnoud M et al. Vitamin D augments glucocorticosteroid efficacy via inhibition of mTORc1. *Mult Scler* 2018; 24 Suppl 2: 33–34
81. Lüssi F & Stangel M. Krankheitsbezogenes Kompetenznetz MS (KKNMS), Hrsg. Praktische Aspekte der Therapie mit Cladribin. München: KKNMS; 2018
82. Cook S et al. Pregnancy outcomes during the clinical development programme of cladribine in multiple sclerosis (MS): an integrated analysis of safety for all exposed patients. *ECTRIMS Online Library* 2017; 199894
83. Holick MF et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011; 96: 1911–1930
84. Spiro A & Buttriss JL. Vitamin D: An overview of vitamin D status and intake in Europe. *Nutr Bull* 2014; 39: 322–350
85. Wagner CL & Hollis BW. The Implications of Vitamin D Status During Pregnancy on Mother and her Developing Child. *Front Endocrinol (Lausanne)* 2018; 9: 500
86. Sintzel MB et al. Vitamin D and Multiple Sclerosis: A Comprehensive Review. *Neurol Ther* 2018; 7: 59–85
87. Hollis BW et al. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. *J Bone Miner Res* 2011; 26: 2341–2357
88. Moon RJ et al. Response to Antenatal Cholecalciferol Supplementation Is Associated With Common Vitamin D-Related Genetic Variants. *J Clin Endocrinol Metab* 2017; 102: 2941–2949
89. Ross AC et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab* 2011; 96: 53–58

Weiterführende aktuelle Literatur:

1. Jasper EA et al. Gestational vitamin D and offspring risk of multiple sclerosis: a systematic review and meta-analysis. *Ann Epidemiol*, Available online 3 Jan 2020; doi.org/10.1016/j.annepidem.2019.12.010
2. Fang X et al. Multiple Sclerosis: Clinical Updates in Women's Health Care Primary and Preventive Care Review. *Obstet Gynecol* 2020; 135(3): 757–758
3. Kalinowska A et al. Recommendations for Neurological, Obstetrical and Gynaecological Care in women with Multiple Sclerosis: A Statement by a Working Group Convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society. *Neurol Neurochir Pol* 2020; Feb 21(online ahead of print)
4. Deems NP & Leuner B. Pregnancy, Postpartum and Parity: Resilience and Vulnerability in Brain Health and Disease. *Front Neuroendocrinol* 2020; Jan 24 (Online ahead of print)

5. Langer-Gould AM. Pregnancy and Family Planning in Multiple Sclerosis. *Continuum (Minneapolis, Minn)*, 2019;25(3):773–792
6. Rezaallah B et al. Social Media Surveillance of Multiple Sclerosis Medications Used During Pregnancy and Breastfeeding: Content Analysis. *J Med Internet Res* 2019;21(8): e13003
7. Smith AL, Cohen JA, Ontaneda D, et al. Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero. *Mult Scler J Exp Transl Clin* 2019; 5(4): 2055217319891744
8. Tisovic K & Amezcua L. Women`s Health: Contemporary Management of MS in Pregnancy and Post-Partum. *Biomedicinis* 2019; 7(2): 32
9. Van Der Walt A et al. Family Planning, Antenatal and Post Partum Care in Multiple Sclerosis: A Review and Update. *Med J Aust* 2019; 211(5): 230–236
10. Houtchens MK et al. Relapses and disease-modifying drugs treatment in pregnancy and live birth in US women with MS. *Neurology* 2018; 91(17): e1570–e1578

Schwerpunkt: Suchterkrankungen

Titel: Der unsichtbare Elefant in der Spielhalle – Potentiale zur Früherkennung von ProblemspielerInnen (S. 34–40)

Autoren: T. Brosowski

Literatur:

1. Banz M & Lang P. Glücksspielverhalten und Glücksspielsucht in Deutschland: Ergebnisse des Surveys 2017 und Trends. Forschungsbericht der BZgA. Köln: Bundeszentrale für Gesundheitliche Aufklärung; 2018
2. Falkain P & Wittchen H. Diagnostisches und statistisches Manual Psychischer Störungen DSM-5. Göttingen: Hogrefe 2018
3. Meyer C et al. Pathologisches Glücksspielen und Epidemiologie (PAGE): Entstehung, Komorbidität, Remission und Behandlung: Endbericht An das Hessische Ministerium des Innern und für Sport. Greifswald, Lübeck 2011
4. Hayer T et al. Das Gefährdungspotenzial von Online-Glücksspielen: Eine systematische Literaturanalyse. Bremen: Universität Bremen 2019
5. Meyer G et al. Die Einschätzung des Gefährdungspotentials von Glücksspielen. *SUCHT* 2010; 56(6): 405–414
6. Loy JK et al. Help-seeking behaviour of problem gamblers: A narrative review. *SUCHT* 2018; 64(5–6): 259–272
7. Rumpf H-J et al. Mini-Review: Recovery without treatment in gambling disorder and problematic gambling. *SUCHT* 2018; 64(5–6): 275–282
8. Moynihan R et al. Preventing overdiagnosis: How to stop harming the healthy. *BMJ*. 2012;344:e3502
9. Hayer T et al. Studie zur Wirkung und Optimierung von Spielersperren und Sozialkonzepten in Spielhallen in Hessen. Wiesbaden: Hessische Ministerium für Soziales und Integration 2018

10. Chagas BT & Gomes JFS. Internet Gambling: A Critical Review of Behavioural Tracking Research. *JGI* 2017; 10(36): 23
11. Currie SR. A research plan to define Canada's first low-risk gambling guidelines. *Health Promot Int* 2018
12. Currie SR et al. Risk of harm among gamblers in the general population as a function of level of participation in gambling activities. *Addiction* 2006; 101(4): 570–580
13. Markham F et al. The relationship between player losses and gambling-related harm: Evidence from nationally representative cross-sectional surveys in four countries. *Addiction* 2015; 111(2): 320–330
14. Nutt DJ & Rehm J. Doing it by numbers: A simple approach to reducing the harms of alcohol. *J Psychopharmacol (Oxford)* 2014; 28(1): 3–7
15. Dowling N et al. The development of empirically derived Australian responsible gambling limits. Melbourne: Victorian Responsible Gambling Foundation; 2018
16. Brosowski T et al. Thresholds of probable problematic gambling involvement for the German population: Results of the Pathological Gambling and Epidemiology (PAGE) Study. *Psychol Addict Behav* 2015; 29(3): 794–804
17. Meyer G et al. Validierung eines Screeninginstruments zur frühzeitigen Identifikation eines problematischen Spielverhaltens in Spielhallen. *Präv Gesundheitsf* 2019; 29(1): 794
18. Gell L et al. Determinants of harmful substance use and harmful gambling. In: Gell L, Bühringer G, McLeod J, et al., eds. *What determines Harm from Addictive Substances and Behaviors*. Oxford: Oxford University Press 2016; 77–111
19. Brosowski T et al. The Gambling Consumption Mediation Model (GCMM): A Multiple Mediation Approach to Estimate the Association of Particular Game Types with Problem Gambling. *Journal of Gambling Studies* 2020. doi:10.1007/s10899-020-09928-3
20. Brosowski T. Ambulante Versorgung von Personen mit Glücksspielproblemen in Niedersachsen – Abgleich mit Bevölkerungsdaten und weitere Detailanalysen: Forschungsbericht an die Niedersächsische Landesstelle für Suchtfragen 2018
21. Brosowski T et al. Das Gambling Consumption Mediation model (GCMM): Durch Mediationsmodelle zur umfassenderen Beurteilung des Zusammenhangs bestimmter Glücksspielformen mit problematischem Glücksspielverhalten. *Suchttherapie* 2019; 20(S 01): 20–02
22. Rehm J et al. The addiction concept revisited. In: Anderson P, Bühringer G, Colom J., eds. *Reframing addictions* 2014: 102–116
23. Hing N et al. Unpacking the public stigma of problem gambling: The process of stigma creation and predictors of social distancing. *Journal of Behavioral Addictions*. 2016; 5(3): 448–456
24. Baggio S et al. Reframing video gaming and internet use addiction: Empirical cross-national comparison of heavy use over time and addiction scales among young users. *Addiction* 2016; 111(3): 513–522
25. Newall P. Dark nudges in gambling. *Addiction Research & Theory* 2018; 27(2): 65–67